skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Emerging options to prevent stroke in atrial fibrillation patients

Review

(698) Views  (211) Full article downloads

Authors: Silver B

Published Date January 2012 Volume 2012:3 Pages 1 - 9
DOI: http://dx.doi.org/10.2147/RRCC.S17427

Brian Silver
Stroke Center, Rhode Island Hospital, Providence, RI, USA

Abstract: Atrial fibrillation is a common condition in the population and increases in prevalence with age. A new method for evaluating stroke risk with atrial fibrillation, called CHA2DS2Vasc, has been developed, as has a novel method for estimating the risk of bleeding, called HAS-BLED. Further, the last decade has seen a dramatic increase in the number of treatment options tested for this condition. These include novel oral anticoagulants such as apixaban, dabigatran, and rivaroxaban, and devices that occlude the left atrial appendage, such as WATCHMAN. This review will compare these new agents with the historical gold standard of warfarin.

Keywords: stroke, atrial fibrillation, treatment







Readers of this article also read:

Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Milnacipran: recent findings in depression
High-density lipoproteins: a novel therapeutic target for cardiovascular disease
Antiplatelet combinations for prevention of atherothrombotic events
Clinical utility of low-density lipoprotein particle measurement in management of cardiovascular disease: a case report
Clinical experience with apixaban in atrial fibrillation: implications of AVERROES
Everolimus-eluting stents: update on current clinical studies
Dabigatran for prophylaxis of thromboembolic events in patients with atrial fibrillation
Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan